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Abstract: Nuclear factor of activated T cells 5 (NFAT5) is the most recently described member of the Rel family of tran-
scription factors, including NF-B and NFAT1-4, which play central roles in inducible gene expression during the im-
mune response. NFAT5 was initially described to drive osmoprotective gene expression in renal medullary cells, which 
are routinely faced by high extracellular osmolalities. Recent data however indicate profound biological importance of the 
mammalian osmotic stress response in view of NFAT5 dependent gene regulation in non-renal tissues. In mononuclear 
cells and epithelial cells, NFAT5 stimulates the expression of various pro-inflammatory cytokines during elevated ambi-
ent tonicity. Accordingly, compared to plasma, the interstitial tonicity of lymphoid organs like spleen and thymus and that 
of liver is substantially hypertonic under physiological conditions. In addition, anisotonic disorders (hypernatremia, diabe-
tes mellitus, dehydration) entail systemic hyperosmolality, and, in inflammatory disorders, the skin, intestine, and cornea 
are sites of local hyperosmolality. This article summarizes the current knowledge regarding systemic and local osmotic 
stress in anisotonic and inflammatory disorders in view of NFAT5 activation and regulation, and NFAT5 dependent cyto-
kine production. 
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INTRODUCTION 
  NFAT5 is the most recently identified member of the Rel 
family of transcription factors including NF-B and nuclear 
factors of activated T cells (NFAT) 1-4 [1, 2]. NFAT5 was 
cloned independently by three groups in 1999 and was des-
ignated as tonicity-responsive enhancer binding protein 
(TonEBP) [3], NFAT5 [4], or osmotic response element 
binding protein (OREBP) [5] – In the following referred to 
as NFAT5. Based on amino acid sequence and structural 
analysis, NFAT5 shares about 40% sequence homology 
within the DNA binding domain with other members of the 
NFAT family [3, 4, 6]. In contrast to NFAT1-4 however, 
NFAT5 lacks a calcineurin-sensitive regulatory domain and 
is therefore not a target for calcineurin inhibitors.  
  Whereas NFAT1-4 are only found in vertebrates, an 
ortholog of NFAT5 has been discovered in Drosophila, sug-
gesting that the role of NFAT5 is not restricted to osmoregu-
latory processes in the kidney medulla in vertebrates, but is 
relevant to responses present in both vertebrates and inverte-
brates [7-9]. In mammalians, investigations addressing the 
function of NFAT5 initially primarily focused on the kidney 
medulla, since the cells of this kidney region are physiologi-
cally exposed to highly elevated interstitial osmolalities as a 
consequence of the operation of the renal concentrating 
mechanism [10]. In this kidney region, NFAT5 regulates the 
expression of various osmoprotective genes that are required 
for normal function and integrity of renal medullary cells 
[10-12]. These include transporters and synthetic enzymes   
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mediating the intracellular accumulation of small, compati-
ble organic osmolytes (i.e. inositol, sorbitol, betaine, taurine, 
glycerophosphocholin) [12]. By this mechanism, renal me-
dulla-resident cells achieve osmotic equilibrium with the 
hyperosmotic extracellular space and thereby prevent cell 
shrinkage and apoptosis [12] (see below). 
  The observation that NFAT5 is expressed in virtually all 
tissues suggests that the function of NFAT5 is not limited to 
the renal medulla [13]. Several additional genes regulated by 
NFAT5 that are not directly involved in cellular osmoadapta-
tion have been identified during the recent years (Table 1). 
These include genes involved in embryogenesis and devel-
opment, tumor metastasis, and hepatic detoxification en-
zymes, suggesting profound biological importance of 
NFAT5 distinct from osmoadaptation. Table 1 summarizes 
these novel findings, although this topic will not be an exten-
sive subject of the present review. 
  In addition to the activation of conserved adaptive 
mechanisms to balance intra- and extracellular osmolalities, 
osmotic stress affects the function of the immune system. 
Hypertonicity stimulates the secretion of pro-inflammatory 
cytokines in immune cells and epithelial cells, and, intrigu-
ingly, several pathologies are associated with local osmotic 
stress within the cellular microenvironment and altered im-
mune responses. These observations suggest that specific 
responses to hyperosmolality are integral part of the immune 
responses by stimulating pro-inflammatory cytokine produc-
tion. 
  The following sections summarize the current knowledge 
regarding local osmotic stress in human disorders and the 
role of NFAT5 activation in view of inflammatory cytokine 
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brief overview of the role of NFAT5 in osmoadaptation and 
the regulation of NFAT5. 
ROLE OF NFAT5 IN OSMOADAPTATION 
  The normal plasma osmolality of 290-300 mosm/kg H20 
is tightly regulated by the release and action of vasopressin, 
and alterations in systemic osmolality entail severe conse-
quences both at the cellular and systemic level [10, 12]. De-
hydration and hence systemic hyperosmolality remain major 
challenges to land organisms because they evolved from the 
sea, where water is readily available. To adapt to fluctuations 
in water availability and intake, land-based mammalians, 
including humans, have developed an effective urinary con-
centrating mechanism, that allows adjustment of water ex-
cretion to the volume status of the body. As a consequence 
of the operation of the urinary concentrating mechanism, 
renal medullary cells are faced by extremely elevated ex-
tracellular osmolalities, which may reach 1,200 mosm/kg 
H20 in humans and may exceed 6,000 mosm/kg H2O in de-
sert rodents [25].  
  Extracellular hyperosmolality entails extraction of water 
from cells, which causes cell shrinkage, a rise in cellular 
ionic strength, an increase in macromolecular crowding, and 
alterations in subcellular architecture [10, 12, 26]. To over-
come these potentially lethal conditions, osmotic stress 
stimulates the transcription of several genes involved in the 
intracellular accumulation of small organic osmolytes, such 
as sorbitol, myo-inositol, betaine, taurine, and others [27]. In 
contrast to electrolytes, organic osmolytes can be enriched 
intracellularly in the range of >500 mmoles/liter without 
detectable negative effects on cellular metabolism or func-
tion [25]. By this mechanism, cells exposed to significant 
osmotic stress achieve osmotic equilibrium with the extracel-
lular space and therefore prevent the harmful effects of hy-
pertonicity. For a comprehensive overview on genomic and 
cellular responses to osmotic stress, the reader is referred to 
recent reviews on this subject [10, 12, 26, 28]. 
REGULATION OF NFAT5 ACTIVITY 
  NFAT5 target genes contain highly conserved sequences 
within their promoter region, known as tonicity responsive 
enhancer (TonE), to which NFAT5 binds and stimulates the 
transcription of the respective target genes [28]. Notably, the 
NFAT1-4 cognate motiv 5'-(T/A/C)GGAA(A/G)-3' is en-
compassed within the NFAT5 recognition site 5'-
TGGAAA(C/A/T)A(T/A)-3' [23]. Accordingly, NFAT5 has 
been demonstrated to bind to NFAT1-4 sites and to stimulate 
transcription, however with lower affinity than other NFAT 
members [29]. Although partial similarities in the core rec-
ognition sequence between NFAT1-4 and NFAT5 have been 
described, activation of NFAT5 differs in several aspects 
from that of NFAT1-4. While members of the NFAT1-4 
family form heterodimers with additional transcription fac-
tors like AP-1, NFAT5-stimulated gene expression requires 
homodimer formation to bind to the respective consensus 
sites [4, 6]. In addition, nuclear translocation of NFAT5 is 
not regulated by the phosphatase calcineurin as in the case of 
NFAT1-4 [30]. 
  Various mechanisms have been described for regulation 
of NFAT5 activity under hypertonic conditions. (i) Hyper-
tonicity causes a rise in intracellular ionic strength, which is 
directly sensed by the N-terminal transactivation domain 
[31-33]. Accordingly, the activity of the latter directly corre-
lates with with extracellular osmolality [31]. (ii) Several 
kinases have been implicated in NFAT5 phosphorylation and 
activation, the most important being p38, Fyn, ATM, and 
PKA, although the upstream activators are incompletely 
characterized [2, 34]. Furthermore, (iii) nuclear translocation 
and (iv) homodimer formation are required for NFAT5-
dependent gene transcription during osmotic stress [35]. (v) 
In yeast and bacteria, a membrane associated osmosensor has 
been identified that signals to the homologue of mammalian 
p38 in response to hypertonicity [36, 37]. Accordingly, we 
have recently identified the EGF receptor as an osmosensi-
tive transmembrane signal transducer that signals to p38 and 
Table 1.  NFAT5 Target Genes not Directly Involved in Osmoadaptation 
Target gene  Cell type  Function  Refs. 
B cell activating factor (BAFF)  B lymphocytes  B lymphocyte proliferation, differentiation, and 
IgG production 
[14] 
beta1,3-Glucuronosyltransferase-I (GlcAT-I)  Nucleus pulposus cells (in-
tervetebral disk) 
Glycosaminoglycan synthesis  [15] 
Cyclooxygenase-2  
(COX-2) 
Renal medullary cells  Prostaglandin synthesis  [16] 
Cytochrome p450 2E1, 3A  Hepatocytes  Drug metabolism  [17, 18] 
HIV replication  Macrophages  Binding of NFAT5  
to LTR required 
[19] 
S100A4/metastasin  Cancer cells  Tumor metastasis  [20, 21] 
Myocyte differentiation  Myoblasts  Cyr61  [22] 
TNF-, lymphotoxin-  T lymphocytes  Immune responses  [23] 
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stimulates NFAT5 transcriptional activity in response to hy-
pertonicity in renal medullary cells [38, 39]. Whether this 
mechanism is also relevant for non-renal cells remains to be 
determined, however a recent study suggested that small G 
proteins and the nucleotide exchange factor Brx contribute to 
NFAT5 activation in lymphocytes exposed to hypertonicity 
[14]. Thus, membrane-associated signaling events in re-
sponse to osmotic stress appear to be a common mechanism 
for NFAT5 activation in different cell types. (vi) Finally, in 
addition to the mechanisms described above, the abundance 
of NFAT5 increases under hypertonic conditions by elevated 
transcription of the NFAT5 gene and by increased stability 
of the respective mRNA [40, 41].  
ROLE OF NFAT5 IN LYMPHOID FUNCTION 
  The concept of isotonicity of body fluids and tissues (ex-
cluding the renal medulla) had to be revised by seminal stud-
ies by Go et al. [42]. The authors provided evidence that the 
interstitium of lymphoid organs like thymus and spleen (and 
also that of liver) is hyperosmolar in the range of 330-340 
mosm/kg H2O compared to plasma with ~300 mosm/kg H2O 
[42]. In heterozygous NFAT5 knockout mice that are viable 
and show partial loss of function, the cellularity of thymus 
and the content of mature T and B cells is diminished by 
~30%, and specific IgG production upon antigenic stimula-
tion is significantly reduced [42]. These defects could be 
reproduced ex vivo in primary lymphoyctes from hypomor-
phic NFAT5 animals, which showed reduced proliferation 
and cytokine production under conditions of moderately ele-
vated extracellular osmolality, which was a functional con-
sequence of impaired osmoadaptation of lympoid cells in 
their local environment of lymphoid organs [42]. This notion 
if further supported by a recent study demonstrating that 
NFAT5 is required to prevent downregulation of cyclins and 
cell cycle arrest during osmotic stress [43]. Further support 
for a significant role of NFAT5 in immune responses stems 
from the observation that NFAT5 is induced in T cells upon 
T cell receptor activation [13] and that NFAT5 is involved in 
the regulation of B cell proliferation, differentiation, and 
immunoglobin production through induction of B cell acti-
vating factor (BAFF) [14]. These observations suggest that 
proper osmoadaptation is an essential component of normal 
lymphoid function and immune responses. Whether inhibi-
tion of NFAT5 might be useful in cases of overstimulation of 
the immune system like autoimmune disorders or transplant 
rejection remains to be determined. 
PATHOLOGIES ASSOCIATED WITH HYPEROS-
MOLALITY AND INFLAMMATION 
  During the recent years it has become increasingly clear 
that local or systemic hyperosmolality is evident during the 
course of various inflammatory disorders (Table 2). Accord-
ingly, a variety of major human pathologies is associated 
with hyperosmolality and inflammatory responses. In some 
conditions, a direct connection between cytokine secretion 
and NFAT5 activation has already been established (Table 
3), in others, it appears highly intriguing to speculate that 
NFAT5 plays a significant role in the initiation and progres-
sion of the disease process. 
  In addition to blood cells, epithelial cells play essential 
roles during the immune response after challenge with ex-
ogenous or endogenous stimuli in view of their ability to 
Table 2.  Pathologies Associated with Local Hypertonicity and Inflammation 
Disorder  Osmolality (mosm/kg H2O) Refs. 
Corneal inflammation in dry  
eye syndrome 
330-365 (tear film)  [47] 
Diabetes mellitus  310-350 (serum)  [48, 49] 
Exercise-induced airway inflammation  
in obstructive pulmonary disorders  
350 (bronchial fluid)  [50] 
Hypernatremia  340 (serum)  [51, 52] 
Inflammatory bowel disease  490 (faeces)  [53, 54] 
 
Table 3.  Systemic Disorders with Proven Involvement of NFAT5 Target Genes 
Condition/Disorder Target  gene  Refs. 
Diabetic microvascular lesions  Aldose reductase 
Inflammatory cytokines? 
[55] 
Adaptive immunity  Genes involved in osmoadaptation 
Immune modulatory cytokines 
B cell activating factor (BAFF) 
[14, 23, 42] 
Salt-sensitive hypertension VEGF-C  [24,  56] Role of NFAT5 in Inflammatory Disorders  Current Genomics, 2010, Vol. 11, No. 8    587 
secrete various cytokines and chemokines [44-46]. Impor-
tantly, direct NFAT5-mediated osmotic regulation of TNF- 
and lymphotoxin- has been demonstrated in T cells [23], 
and IL-1, IL-6, and IL-18 contain putative NFAT5 consensus 
sites in their promoter region and are regulated in a NFAT5 
dependent manner under hypertonic conditions (unpublished 
result). The following section summarizes the available 
knowledge on the role of NFAT5 in pathologies associated 
with local or systemic hyperosmolality. 
NFAT5 and Diabetic Microvascular Lesions 
  Up to 50% of patients with type 1 and type 2 diabetes 
will develop microvascular complications during the course 
of the disease, including diabetic neuropathy, retinopathy, 
and nephropathy [57]. It is generally accepted that chronic 
inflammation and dysregulation of the immune system play 
important roles in the development of microvascular lesions 
in diabetes. Hyperglycemia may result in significant plasma 
hyperosmolality in the range of 310-350 mosm/kg H2O, and 
postprandial hyperglycemia frequently occurs even when 
metabolic control is apparently good [49, 58, 59]. In addi-
tion, oscillatory hyperglycemia as routinely found in most 
patients, causes more acute increases in plasma concentra-
tions of pro-inflammatory cytokines including IL-6, IL-18, 
and TNF-, as compared to chronic hyperglycemia [60]. In 
support of the notion that hyperosmolality is linked to cyto-
kine expression, exposure of human peripheral blood mono-
cytic cells (PBMC) to hyperosmotic conditions (330-410 
mosm/kg H2O) induces expression of IL-1 and IL-8 [61]. 
Indeed, increased DNA binding activity of NFAT5 to TonE 
is significantly increased in PBMC from patients with mi-
crovascular lesions compared with diabetic control subjects 
[62]. Since TNF- is a direct NFAT5 target gene in immune 
cells [23] and IL-1, IL-6 and IL-18 contain NFAT5 binding 
sites in their promoter region (unpublished result), it is read-
ily conceivable that NFAT5 plays a causal role in inflamma-
tory processes as observed in diabetic microvascular lesions. 
These observations indicate that persistent or intermittent 
hyperosmolality, as present in diabetic subjects, is sufficient 
for activation of NFAT5 and likely inflammatory cytokine 
secretion. 
  It is well established that hyperglycemia results in in-
creased glucose metabolization through the polyol pathway 
[63], which has been linked to abnormalities found in dia-
betic microvascular disease. In the first rate-limiting step, 
glucose is reduced to sorbitol by the enzyme aldose reduc-
tase (AR) by the usage of NADPH [64]. In the second step, 
sorbitol is oxidized to fructose by sorbitol dehydrogenase. 
This metabolic pathway entails reduced cellular NADPH and 
consequently gluthatione levels, which may predispose to 
oxidative stress-induced damage [65]. In addition, elevated 
fructose levels increase the formation of advanced glycosyla-
tion end products [65]. The notion that NFAT5 is causally 
linked to these events is supported by the observation that 
AR is a prototypical NFAT5 target gene [66], and that 
NFAT5 shows increased DNA binding activity to its consen-
sus sequence in PBMC from patients with diabetic mi-
crovascular complications compared with diabetic control 
subjects under hyperglycemic conditions [62]. Furthermore, 
enhanced expression of AR is observed in peripheral nerve 
and renal glomeruli in diabetic patients, and the degree of 
expression correlates with the disease score [67]. 
  Data regarding NFAT5 inhibition are lacking so far, 
however, orally available AR inhibitors have been developed 
over the recent 25 years and tested in clinical trials [55]. The 
results were however mixed and several substances had to 
been withdrawn from human use because of adverse side 
effects. Currently, only one compound (epalrestat) is ap-
proved in Japan. Future work is required to address the ques-
tion whether inhibition of NFAT5 might be suitable to ame-
liorate diabetic microvascular complications. We are cur-
rently testing this exciting hypothesis in conditional NFAT5 
knockout mice. 
Role of NFAT5 in Blood Pressure Regulation and So-
dium-Sensitive Hypertension 
  Salt sensitive hypertension describes a reproducible con-
dition between salt intake and blood pressure, and the devel-
opment of arterial hypertension [68]. During the recent dec-
ade, the concept of isotonicity of body fluids (i.e. the plasma 
and tissue interstitium) had however to be revised. Studies 
by the group of Titze convincingly demonstrated that sodium 
can be accumulated in the interstitium of the skin without 
commensurate water retention, and this skin sodium storage 
is paralleled by increased polymerization and sulfation of 
skin glycosaminoglycans, thereby increasing their ability for 
sodium storage [69-71]. Indeed, a high salt diet in rats causes 
hypertonic sodium storage within the interstitium of the skin, 
and this condition correlates with the development of arterial 
hypertension [24]. The ensuing local osmotic stress is sensed 
by skin macrophages, which activate the NFAT5 pathway. 
  We could identify vascular endothelial growth factor 
(VEGF)-C as a direct NFAT5 target gene in macrophages. 
Accordingly, the synthesis of VEGF-C increases in a 
NFAT5-dependent manner in skin macrophages of rats fed a 
high salt diet and in macrophages exposed to hypertonicity 
in vitro [24]. In consequence, VEGF-C induces hyperplasia 
and increased density of the skin lymphcapillary network, 
which buffers hypertension. Conversely, blocking NFAT5 or 
VEGF-C signalling aggravates hypertension. Thus, NFAT5–
VEGF-C signalling in skin macrophages is a major determi-
nant of extracellular volume and hence blood pressure ho-
meostasis under conditions of high salt intake [24]. 
Inflammatory Bowel Disease 
  Human inflammatory bowel disease (IBD), the most im-
portant entities being Crohn's disease and ulcerative colitis, 
are chronic and relapsing inflammatory conditions that result 
from chronic dysregulation of the mucosal immune system 
in the gastrointestinal tract [72]. 
  Elevated levels of pro-inflammatory cytokines, including 
IL-1, IL-6, IL-18, and TNF- are detected in active IBD, and 
correlate with the severity of inflammation, the degree of 
mucosal permeability leak, and leukocyte infiltration [73-
75]. The major source of inflammatory cytokines are colonic 
epithelial cells and possibly infiltrating immune cells. In-
triguingly, patients with Crohn's disease present with sub-
stantially higher osmolality of the faecal fluid compared to 588    Current Genomics, 2010, Vol. 11, No. 8  Wolfgang Neuhofer 
control subjects (~490 vs. ~340 mosmol/kg H2O), and faecal 
hyperosmolality correlates with the histological disease score 
[53, 54]. Given the fact that colonic epithelial cells express 
aquaporins in their apical membrane, luminal hyperosmolal-
ity is expected to translate into intracellular osmotic stress 
and hence NFAT5 activation, which is abundantly expressed 
in colonic epithelial cells [21]. Although a direct causal link 
between the inflammatory process and NFAT5 activation is 
currently missing, the availability of mouse models with 
characteristics similar to human IBD and the use of condi-
tional NFAT5 knockout mice will hopefully shed further 
light on this subject.  
Miscellaneous 
  Diverse other conditions are characterized by local os-
motic stress, which correlates with the secretion of pro-
inflammatory cytokines by the respective cell type, although 
a direct functional role of NFAT5 has not been demonstrated 
yet (See also Table 2). 
  Exercise-induced bronchoconstriction and inflammation 
occurs frequently in patients with bronchial asthma or 
chronic obstructive pulmonary disease with a delay of 2-13 
hours after exercise [76, 77]. Evaporation of water across 
airway epithelia results in substantial local hyperosmolality 
of the airway mucosa (Table 2) [78]. Accordingly, human 
respiratory epithelia shrink after apical exposure to hyper-
tonic saline, which causes epithelial cell activation, along 
with secretion of IL-8 and RANTES [79-81]. The latter ef-
fects require p38 MAP kinase activity, which is an estab-
lished upstream activator of NFAT5 [81, 82]. Whether 
NFAT5 plays a causal role in this process is currently un-
known, however, both IL-8 and RANTES harbor NFAT5 
target sequences in their promoter region (unpublished re-
sult). 
  Hyperosmolality of the tear film is regarded as the major 
factor in the pathogenesis of corneal inflammation in dry eye 
syndrome, which is a highly prevalent condition affecting 
10-20% of adults [47, 83-86]. Osmolalities up to 365 
mosm/kg H2O have been reported in patients with sicca syn-
drome, while it was 280-300 mosm/kg H2O in normal sub-
jects [47] (Table 2). Accordingly local osmotic stress is as-
sociated with elevated concentrations of IL-1, IL-6, TNF-, 
and others in the tear film and induction of the respective 
mRNAs in corneal and conjunctival epithelia, and cytokine 
levels correlate with clinical parameters [87, 88]. 
  Hypernatremia is a serious electrolyte disorder leading to 
substantially elevated plasma osmolality, representing a 
strong and independent risk factor for mortality in hospital-
ized patients [51, 89]. Hypernatremia may result from vari-
ous causes, including faecal fluid losses, diabetes insipidus, 
diuretic use, burns, inadequate hypertonic fluid therapy, de-
hydration after exercise, heat stroke, and others. Due to the 
relative excess of sodium to water in the extracellular fluid, 
plasma osmolalities may exceed 340 mosm/kg H2O [89]. 
Severe hypernatremia is associated with increased circulat-
ing levels of inflammatory mediators including IL-6, IL-10, 
and TNF-, even in the absence of an infective focus [89, 
90]. Given the fact that immune cells produce these cytoki-
nes in response to osmotic stress, it is readily conceivable 
that this event is mediated by activation of NFAT5. 
CONCLUDING REMARKS 
  Recent studies on NFAT5 function primarily focused on 
osmoadaptation of renal medullary cells, however emerging 
evidence suggests profound biological importance of NFAT5 
activation in view of local hyperosmolality associated with 
inflammation as found in many human pathologies. Further 
investigation of this hypothesis in NFAT5 knockout mice 
has been largely hampered by dramatically reduced embry-
onic viability and a high degree of early perinatal lethality in 
homozygeous NFAT5-deficient mice [42]. To overcome this 
limitation, we have recently generated conditional NFAT5 
knockout mice, which will hopefully shed further light on 
the function of NFAT5 in the course of inflammatory disor-
ders. In addition, future experiments are required to clarify 
whether inhibition of NFAT5 might be a suitable target for 
treatment of inflammatory pathologies associated with os-
motic stress. 
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